Trial Profile
A Randomized, Open-label Study of Dapagliflozin in Patients With or Without Type 2 Diabetes Admitted With Acute Heart Failure
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Bumetanide; Diuretics; Diuretics; Furosemide
- Indications Decompensated heart failure; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms DICTATE-AHF
- 21 Aug 2023 According to an AstraZeneca media release, data from this study will be presented at the European Society of Cardiology (ESC) Congress 2023.
- 17 May 2023 Status changed from recruiting to completed.
- 06 Feb 2023 Planned End Date changed from 31 Jan 2023 to 31 Dec 2023.